IL‐4‐treated BMDMs promote glioma clustering, unlike LPS‐treated BMDMs, suggesting that tumor‐associated BV2 cells were driven to an anti‐inflammatory phenotype that restricts proliferation while preserving antitumor immunity. The gene discussed is IL4; the disease is glioma.